ANCN - Anchiano Therapeutics Ltd

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.3868
-0.0432 (-3.02%)
As of 11:05AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.4300
Open1.3900
Bid1.3800 x 4000
Ask1.3900 x 1200
Day's Range1.3600 - 1.4500
52 Week Range1.0400 - 11.5000
Volume38,832
Avg. Volume36,390
Market Cap10.29M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.5380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

    Anchiano Therapeutics Ltd. (ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on or about March 23, 2020. The matters raised by Access Industries Holdings LLC and Clal Biotechnology Industries Ltd. will be addressed at the Annual Meeting. Holders of the Company’s ordinary shares and holders of the Company’s American Depositary Shares at the close of business on February 17, 2020, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.

  • GlobeNewswire

    Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass., Nov. 15, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies.

  • GlobeNewswire

    Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program

    After a thorough analysis of the data, Anchiano determined that there is a low probability of surpassing the pre-defined futility threshold at the planned interim analysis, which required 10 complete responses in 35 patients. The data also indicate a low probability of achieving an efficacy profile that in the company’s estimation would be necessary to support regulatory approval.

  • GlobeNewswire

    Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board

    Anchiano Therapeutics Ltd. (ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today announced Stephen Hoffman, M.D., Ph.D. is stepping down from the Board of Directors effective immediately. “Steve led the company through the initiation of its pivotal clinical trial Codex, to its public offering and Nasdaq listing, and the recent acquisition of its RAS-inhibitor program,” said Frank Haluska M.D., Ph.D., President and Chief Executive Officer of Anchiano.

  • GlobeNewswire

    Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

    Anchiano Therapeutics Ltd. (ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today reported that Anchiano Therapeutics, Inc., the Company’s U.S. subsidiary, has entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharmaceuticals, LLC (“ADT”) to develop novel small-molecule inhibitors of RAS and PDE10/β-catenin. This collaboration reflects Anchiano’s ongoing strategy to grow a pipeline beyond its pivotal-stage asset, inodiftagene vixteplasmid, with programs that have the potential to address significant clinical needs, while leveraging Anchiano’s expertise in small-molecule oncology development.

  • GlobeNewswire

    Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

    CAMBRIDGE, Mass., Sept. 20, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development.

  • GlobeNewswire

    Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development.

  • GlobeNewswire

    Anchiano Therapeutics Reports Second Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Aug. 05, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of.

  • GlobeNewswire

    Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange

    CAMBRIDGE, Mass., June 18, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of.

  • GlobeNewswire

    Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development

    Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of Salar Roshan as the Company’s Head of Business Development, effective May 28, 2019. Mr. Roshan will report to the Chief Executive Officer and will focus on driving Anchiano’s strategic initiatives.

  • GlobeNewswire

    Anchiano Therapeutics Reports First Quarter 2019 Financial Results

    – Closed $30.5 million U.S. Initial Public Offering in February 2019 – CAMBRIDGE, Mass., May 22, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a.

  • GlobeNewswire

    Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference

    CAMBRIDGE, Mass., March 14, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and.

  • GlobeNewswire

    Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange

    Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced an update with respect to its intention to voluntarily delist its ordinary shares, no par value (the “Ordinary Shares”), from the Tel Aviv Stock Exchange Ltd. (the “TASE”). In accordance with applicable Israeli law and the rules of the TASE, the last day the Ordinary Shares will trade on the TASE will be June 13, 2019, and the Ordinary Shares will be delisted from the TASE on June 17, 2019.

  • GlobeNewswire

    Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    – Successfully Completed $30.5 million U.S. Initial Public Offering in February 2019 – –  Interim Analysis of the Codex Clinical Trial Expected in Fourth Quarter 2019  –.

  • GlobeNewswire

    Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering

    Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS resulting in gross proceeds of $30.5 million. The ADSs began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019. The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any.

  • GlobeNewswire

    Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering

    Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to close on or about February 14, 2019. The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any.

  • Benzinga

    IPO Outlook For The Week: Biotechs And Another Virgin Group Addition

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...